Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 21;19(1):67.
doi: 10.1186/s12890-019-0827-5.

The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients

Iain Armstrong  1   2 , Catherine Billings  3   4 , David G Kiely  3   5 , Janelle Yorke  6 , Carl Harries  7 , Shaun Clayton  4 , Wendy Gin-Sing  8
Affiliations

The patient experience of pulmonary hypertension: a large cross-sectional study of UK patients

Iain Armstrong et al. BMC Pulm Med. .

Abstract

Background: Pulmonary Hypertension Association UK (PHA-UK) is the only charity in the UK especially for people affected by pulmonary hypertension (PH). To better understand the impact of PH on patients and carers beyond clinical symptoms, the PHA-UK carried out a cross-sectional survey on the effect of PH on daily living, along with a follow-up survey assessing the financial impact of PH.

Methods: This is a descriptive cross-sectional survey of adult patients with PH in the UK. A quantitative survey of four key topics (time to diagnosis, quality of life [QoL], financial impact and specialist treatment), was made available to PHA-UK members and patients on PH therapy, with a follow-up financial impact survey sent to those responders who agreed to be contacted further. Data collection was carried out in January and February 2017 for the main survey, and November and December 2017 for the financial impact survey.

Results: The main survey was completed by 567 individuals, and the financial follow-up survey by 171. Mean age of responders was 69 ± 17 years with 70% female. 60% of respondents said PH had a major impact on their QoL, with 45% reporting that treatment and management improves their QoL 'a lot'. The time between first experiencing symptoms and diagnosis was ≥1 year for 48% of patients, with 40% seeing 4+ doctors before diagnosis. 63% of patients reported financial worries. Patients in part-time and full-time work reported the greatest financial burden, with a 13 and 33% fall in monthly income respectively. Patients had positive experiences of treatment in specialist centres, with 62% rating their care 'excellent', and 92% saying they preferred travelling to a specialist centre rather than seeing a local non-specialist.

Conclusions: This study reports the largest UK survey exploring issues affecting patients with PH. The study shows that despite the availability of new therapies, patients are still experiencing delays prior to diagnosis, and experiencing both emotional and financial impacts from the disease. By identifying the areas patients find most important in their treatment, this research can inform future care policies and long-term management to support patients living with PH and their families.

Keywords: PHA-UK; Patient survey; Pulmonary hypertension; Real-life research.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Ethical approval was not requested for the study, as no NHS or patient data were collected outside of the survey responses. The waiving of the need for ethical approval in this context complies with national guidelines from the NHS Health Research Authority and international guidelines from the Declaration of Helsinki. For all participants filling in questionnaires, informed consent was given by virtue of completing and sending back the form, while verbal consent was obtained for all participants undertaking the telephone interviews.

Consent for publication

Not applicable.

Competing interests

IA has received funding to attend educational meetings and received personal fees for lectures and attendance at advisory board meetings from Actelion, Bayer, GSK and MSD.

CB has nothing to disclose.

DGK has received funding to attend educational meetings and received personal fees for lectures and attendance at advisory board meetings from Actelion, Bayer, GSK and MSD. The department in which he works has also received grant funding from Actelion, Bayer and GSK.

JY has received funding to attend educational meetings and received personal fees for lectures and attendance at advisory board meetings from Actelion, Bayer and GSK.

CH has received funding to attend educational meetings and received personal fees for lectures and attendance at advisory board meetings from Actelion, MSD, Bayer and GSK.

SC has nothing to disclose.

WGS has received funding to attend educational meetings and received personal fees for lectures and attendance at advisory board meetings from Actelion, Bayer, GSK and MSD.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Effect of PH on QoL. (a) The impact of PH disease on QoL measures. (b) The effect of PH treatment and management on QoL measures
Fig. 2
Fig. 2
Treatment priorities
See this image and copyright information in PMC

References

    1. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol. 2013;62:D42–D50. doi: 10.1016/j.jacc.2013.10.032. - DOI - PubMed
    1. Hoeper MM, Humbert M, Souza R, Idrees M, Kawut SM, Sliwa-Hahnle K, Jing ZC, Gibbs JS: A global view of pulmonary hypertension. Lancet Respir Med 2016;4:306–22. - PubMed
    1. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006;173:1023–1030. doi: 10.1164/rccm.200510-1668OC. - DOI - PubMed
    1. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, et al: Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010;137:376–87. - PubMed
    1. Brown LM, Chen H, Halpern S, Taichman D, McGoon MD, Farber HW, Frost AE, Liou TG, Turner M, Feldkircher K, et al. Delay in recognition of pulmonary arterial hypertension: factors identified from the REVEAL registry. Chest. 2011;140:19–26. - PMC - PubMed